Top Markets
#1 Useless Coin Useless Coin +39.98%
#2 StonkBroker StonkBroker +38.07%
#3 Merlin's Seal BTC Merlin's Seal BTC +37.69%
#4 0G 0G +34.77%
#5 SAFEcoin SAFEcoin +30.08%
#6 Dogs Dogs +19.32%
#7 Arbitrum Arbitrum +18.58%
#8 Full Moon Full Moon +17.84%
#9 Zora Zora +17.77%
#10 Notcoin Notcoin +17.21%
Coin of the day
Useless Coin Useless Coin
設定
言語
日本
通貨
USD
テーマ
Evommune, Inc. Evommune, Inc.

Evommune, Inc.

EVMN
株式のランク #13820
Evommune, Inc. is a United States-based clinical-stage biotechnology company... Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
株価
$12.63
時価総額
$458.19M
変化（1日）
-3.26%
変化（1年）
-
国
US
取引 Evommune, Inc. (EVMN)

カテゴリー

Healthcare
Evommune, Inc.（EVMN）の収益
Aug 2026 時点の収益 TTM: 0
Evommune, Inc. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Evommune, Inc. の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH